1Y Close · As of Aug 26, 2026
JEIL PHARMA HOLDINGS operates in the Architecture & Engineering sector.
Legal name: JEIL PHARMA HOLDINGS INC.
In fiscal year 2025, JEIL PHARMA HOLDINGS (002620) reported revenue of 657.6 billion KRW, down 15.7% from 779.8 billion KRW a year earlier.
Operating profit was 38.7 billion KRW and net income was 34.6 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 118.4 billion KRW, with a P/B of 0.25.
These figures can be verified in the DART filing (receipt no. 20260316001198).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2025 | 657.6B | 38.7B | 34.6B |
| 2024 | 779.8B | -11.6B | -66.4B |
| 2023 | 804.0B | 20.8B | -13.2B |
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Semi-Annual Report (2026.06) |